# Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25mg With Those of Enbrel®

> **NCT01725620** · PHASE1 · COMPLETED · sponsor: **LG Life Sciences** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LBEC0101 (Etanercept 25mg)
- **DRUG:** Enbrel (Etanercept 25mg)

## Key facts

- **NCT ID:** NCT01725620
- **Lead sponsor:** LG Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2013-04
- **Final completion:** 2014-04
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2015-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01725620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01725620, "Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25mg With Those of Enbrel®". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01725620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*